share_log

Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Benzinga ·  Jul 24, 2023 08:57

Maxim Group analyst Jason McCarthy upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and announces $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment